Latest Lausanne Stories

EPFL's Brain Mind Institute finds clues to the role of brain plaques typical in Alzheimer's patientsA study from EPFL's (Ecole Polytechnique Fédérale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration....

HOUSTON and BOULDER, Colo., Feb. 28 /PRNewswire/ -- A two-year investigation of online Olympics ticket scams has identified defrauded consumers throughout the world and dubious ticketing practices by the International Olympic Committee (IOC), according to the Moriarty Leyendecker law firm. Hundreds of consumers - including families and friends of Olympic athletes - have been defrauded by official-looking ticketing web sites or failed to receive tickets from "gray market" resellers during...

LAUSANNE, Switzerland, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV)...

The world of IT pursues its race for performance. CMOSAIC could boost the computing performance of central processors by a factor 10 while consuming less energy. The IBM Research Laboratory has joined EPFL and ETH Zurich - the two Swiss Federal Institutes of Technology "“ in this project of national scope supported by the Swiss National Science Foundation (SNSF) via its Nano-Tera programme.3D microprocessors cooled from the inside through channels as thin as a human hair filled with a...

LAUSANNE, Switzerland, October 12 /PRNewswire/ -- SmallRivers, specialized in the development of distributed web services, just launched its new service. It allows content editors and bloggers to clip an intelligent micro-code on their content, providing their viewers with immediate access to related content and blog discussions published elsewhere on the web, as well as the possibility to interact with the viewers of these other sites; all without ever leaving the initial site. In...

LAUSANNE, Switzerland, October 5 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for...

PARIS and LAUSANNE, Switzerland, September 7 /PRNewswire/ -- Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class...

LAUSANNE, Switzerland, September 3 /PRNewswire/ -- Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection. Funded by Debiopharm, the ceremony took...

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in...

LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that Salvacyl(R) (also known under the trade names Moapar(R) and Salvapar(R)), was launched in Germany in May 2009, by Dr R. Pfleger GmbH. In April 2009, Salvacyl(R) was also launched on a preliminary basis in Belgium. The effective commercial launch will...